SCM
BIVV

Segantii Capital Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Segantii Capital Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,087
Closed -$59K – 369
2017
Q1 		$59K Buy
+1,087
New +$53.5K 0.01% 260

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Segantii Capital Management's BIVV Position: Q2 2017 in Review

Segantii Capital Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 1,087 shares — an estimated $59K sold.

Segantii Capital Management first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $59K in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Segantii Capital Management reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 1,087 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $59K.
  • Segantii Capital Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Bioverativ Inc. Common Stock position peaked at $59K in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.